# Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C

> **NCT00122616** · PHASE3 · COMPLETED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 52 (actual)

## Conditions studied

- HIV Infections
- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** Peginterferon alpha-2a (Pegasys®)
- **DRUG:** Ribavirin
- **DRUG:** HIV antiretroviral therapy
- **DRUG:** HIV antiretroviral therapy

## Key facts

- **NCT ID:** NCT00122616
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2012-02-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122616, "Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00122616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*